These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

860 related items for PubMed ID: 14964744

  • 1. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE.
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W.
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [Abstract] [Full Text] [Related]

  • 3. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
    Ortonne JP, Shear N, Shumack S, Henninger E, CLEAR Multinational Study Group.
    BMC Dermatol; 2005 Dec 16; 5():13. PubMed ID: 16359548
    [Abstract] [Full Text] [Related]

  • 4. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A, Efalizumab Study Group.
    JAMA; 2003 Dec 17; 290(23):3073-80. PubMed ID: 14679270
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials.
    Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA.
    Health Qual Life Outcomes; 2003 Oct 08; 1():53. PubMed ID: 14613569
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
    Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A, Efalizumab Study Group.
    Int J Dermatol; 2006 May 08; 45(5):605-14. PubMed ID: 16700803
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG.
    Br J Dermatol; 2010 Jan 08; 162(1):137-46. PubMed ID: 19903183
    [Abstract] [Full Text] [Related]

  • 11. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA.
    Health Qual Life Outcomes; 2006 Sep 27; 4():71. PubMed ID: 17005043
    [Abstract] [Full Text] [Related]

  • 12. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.
    J Dermatolog Treat; 2007 Sep 27; 18(6):341-50. PubMed ID: 18058494
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.
    Br J Dermatol; 2005 May 27; 152(5):954-60. PubMed ID: 15888152
    [Abstract] [Full Text] [Related]

  • 16. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
    Augustin M, Lambert J, Zema C, Thompson EHZ, Yang M, Wu EQ, Garcia-Horton V, Geng Z, Valdes JM, Joshi A, Gordon KB.
    JAMA Dermatol; 2020 Dec 01; 156(12):1344-1353. PubMed ID: 33052382
    [Abstract] [Full Text] [Related]

  • 17. Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
    Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M.
    J Cutan Med Surg; 2005 Dec 01; 9(6):303-12. PubMed ID: 16699904
    [Abstract] [Full Text] [Related]

  • 18. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.
    Dermatology; 2008 Dec 01; 216(3):260-70. PubMed ID: 18187944
    [Abstract] [Full Text] [Related]

  • 19. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
    Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A.
    Br J Dermatol; 2008 Mar 01; 158(3):549-57. PubMed ID: 18047521
    [Abstract] [Full Text] [Related]

  • 20. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
    Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D, Efalizumab Study Group.
    N Engl J Med; 2003 Nov 20; 349(21):2004-13. PubMed ID: 14627785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.